4.0 Article

Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma

Journal

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Volume 30, Issue 1, Pages 46-52

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPH.0b013e31815d1d6f

Keywords

alveolar soft part sarcoma (ASPS); ASPL-TFE3 type 1 and 2 antibodies; gene fusion epitope detection

Funding

  1. NCI NIH HHS [N01-CO-12400] Funding Source: Medline
  2. NATIONAL CANCER INSTITUTE [ZICBC011087] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Alveolar soft part sarcoma (ASPS), a rare soft tissue sarcoma, is characterized by a chromosomal translocation der(17)t(X;17)(p11;q25) resulting in the production of 2 fusion proteins encoded by regions of the genes for alveolar soft part locus (ASPL) and the transcription factor E3 (TFE3). In this study, polyclonal antibodies were generated to 25 mer peptides encompassing the junctional regions of ASPL-TFE3 type 1 and ASPL-TFE3 type 2. The specificity of the affinity purified antibodies for the synthetic peptides and recombinant expressed ASPL-TFE3 type 1 and ASPL-TFE3 type 2 proteins was evaluated by enzyme-linked immunosorbent assay and was highly fusion type specific. Immunohistochemical staining of formalin-fixed, paraffin-embedded ASPS tumors with the fusion-specific antibodies resulted in intense nuclear staining and differentiation between tumors that express the type 1 protein and tumors that express the type 2 protein. These antibodies will be useful for the differential diagnosis of type 1 and type 2 ASPS and also in the detection of the fusion proteins in biochemical and cell biologic investigations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available